

## UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/508,098	3 03/16/0	0 ZUCHT		. Н	P65141US0
			$\neg$		EXAMINER
000136		HM12/083	0		<u> </u>
JACOBSON HOLMAN PLLC				MOFZIE.F	
400 SEVENTH STREET N.W.				ART UNIT	PAPER NUMBER
SUITE 600					Cl
WASHINGTON DC 20004				1653	7
				DATE MAILED:	
					09/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No. 09/508,095

Applicant(s)

**FORSSMANN** 

Examiner

F. MOEZIE

Art Unit **1653** 

The MAILING DATE of this communication appears	on the cover sheet with the correspondence address		
P riod for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.	TTO EXPIRE <u>one</u> MONTH(S) FROM		
<ul> <li>Extensions of time may be available under the provisions of 37 0 after SIX (6) MONTHS from the mailing date of this communi</li> <li>If the period for reply specified above is less than thirty (30) day</li> </ul>	cation.		
be considered timely.  - If NO period for reply is specified above, the maximum statutory	period will apply and will expire SIX (6) MONTHS from the mailing date of this		
	y statute, cause the application to become ABANDONED (35 U.S.C. § 133). e mailing date of this communication, even if timely filed, may reduce any		
Status			
1) $\  \  \  \  \  \  \  \  \  \  \  \  \ $	and 8/21/01 .		
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ This ac	ction is non-final.		
3) Since this application is in condition for allowance closed in accordance with the practice under Ex particle.	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.		
Disposition of Claims			
4) X Claim(s) 1 and 3-5	is/are pending in the application.		
4a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) Claim(s)	is/are allowed.		
6) Claim(s)	is/are rejected.		
7)  Claim(s)	is/are objected to.		
8) 🔀 Claims <u>1 and 3-5</u>	are subject to restriction and/or election requirement.		
Application Papers			
9) The specification is objected to by the Examiner.			
10) The drawing(s) filed on is/ar-	e objected to by the Examiner.		
11) The proposed drawing correction filed on	is: a)□ approved b)□ disapproved.		
12) The oath or declaration is objected to by the Exam	niner.		
Priority under 35 U.S.C. § 119			
13) Acknowledgement is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)-(d).		
a) $\square$ All b) $\square$ Some* c) $\square$ None of:			
1. $\square$ Certified copies of the priority documents ha	ve been received.		
2. Certified copies of the priority documents ha	ve been received in Application No		
3. Copies of the certified copies of the priority of application from the International Burd*See the attached detailed Office action for a list of the action for a list of			
14) Acknowledgement is made of a claim for domestic			
•	- Friend, 1 1001 00 010101 0 110101		
Attachment(s)			
<ul> <li>15) Notice of References Cited (PTO-892)</li> <li>16) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> </ul>	18) Interview Summary (PTO-413) Paper No(s)		
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:		

## **DETAILED ACTION**

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4 and 5, drawn to peptide sequences.

Group II, claim 5, drawn to nucleic acid coding sequences.

2. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: they lack the same technical features, amino acids for peptides do not correspond to the special technical features for nucleic acid sequences.

In the event that Group I invention is elected, applicant is further required to comply with a second election requirement as follows: to elect **one peptide sequence** from among the peptide sequences designated as SEQ ID NO:1-24, cited in claim 5. The sequences lack a special technical features because each peptide sequence has its special length and its special amino acid arrangement(s) in its sequence which does not correspond to other peptide sequences.

In the event that Group II invention is elected, applicant is further required to comply with a second election requirement as follows: to elect **one nucleic acid encoding sequence** from among the various sequences encompassed by claim 3. The sequences lack a special

Application/Control Number: 09/508,095 Page 3

Art Unit: 1653

technical features because each nucleic acid encoding sequence has its special length and arrangement which does not correspond to other sequences.

Applicant is advised that the reply to this requirement to be complete must include an election of: a) Invention I or II followed by b) an election of a single peptide sequence or nucleic acid encoding sequence, to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F.T. Moezie whose telephone number is (703) 305-4508 or Dr. LOW (SPE) at 308-2923.

J. J. Moega